The irritable bowel syndrome (IBS) market has experienced slow growth owing to a lack of disease understanding, low rate of patients seeking treatment, and few effective therapies that treat all symptoms of the disease. Existing agents primarily treat motility symptoms, with few effects on pain, discomfort, and/or the underlying cause of the disease. Furthermore, development of drugs specifically indicated for the diarrhea-predominant form remains elusive. DRG anticipates a market shift over the next ten years, especially in the constipation-predominant form of IBS, with development and launch of two new therapies: tenapanor and prucalopride. Tenapanor has a novel mechanism of action, has demonstrated good clinical efficacy, and is poised to disrupt the current market by providing relief for pain symptoms, which are of greatest concern to patients.


What are the key areas of unmet need and opportunity in IBS and within IBS subtypes? · What is the expected impact of novel therapy launches over the next ten years, and how might these launches impact opportunities in the IBS market? · What influence does each major player hold over the IBS market? · How is the IBS market expected to change over the next ten years?


United States Primary Research 3 KOL interviews in October 2018


Allergan, Takeda, Ardelyx, Shire


Viberzi, tenapanor, prucalopride, Linzess

Table of contents

  • Irritable Bowel Syndrome - Executive Insights - Executive Insights (US)
    • Irritable Bowel Syndrome | Executive Insights

Author(s): Meghan Hennis, Ph.D.; Matthew W. Scutcher, MEng PhD

Meghan Hennis, PhD is a Senior Analyst in the New Product Development group at Decision Resources Group. She has over 10 years of research experience in the biological sciences followed by 2 years as part of the Consulting team at DRG where she provided key insights to client business questions across a range of therapeutic areas. Dr. Hennis received her Ph.D. in Neuroscience from University of Texas Southwestern Medical Center and her B.S. in Biology from University of North Carolina Chapel Hill.

Matthew Scutcher is Therapy Leader for the Immune & Inflammatory research team at DRG.  

In this role, he leads a team of 13 Research Associates, Business Insights Analysts and Directors responsible for analyzing some of the largest and most dynamic markets in the pharmaceutical industry

He has been with DRG since 2009 and holds a Ph.D. from University College London and a Master’s degree in Chemical Engineering from Imperial College London.